GlassScriptPhysician profile
Jackie H Johnson
NPI 1679707541
$3,212.00
in general payments reported to CMS, 2019-2025
21 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $505 · 2021: $793 · 2022: $394 · 2023: $199 · 2024: $715 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $982.40 | 2019-2025 | Clareon, Unity, Lensx |
| Johnson & Johnson Surgical Vision, INC. | $356.50 | 2019-2023 | Catalys System |
| Sun Pharmaceutical Industries INC. | $276.17 | 2019-2023 | Cequa |
| Kala Pharmaceuticals, INC. | $245.83 | 2019-2021 | |
| Allergan, INC. | $222.36 | 2020-2021 | |
| Glaukos Corporation | $181.46 | 2020-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Eyevance Pharmaceuticals LLC | $135.03 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.79 | 2019-2021 | |
| Astellas Pharma US INC | $124.66 | 2024 | Izervay |
| Abbvie INC. | $120.81 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $87.84 | 2022-2025 | Envista Mx60 Iol, Envista Envy Iol |
| Tarsus Pharmaceuticals, INC. | $81.58 | 2024-2025 | Xdemvy |
| Rxsight INC | $71.57 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Shire North American Group INC | $39.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $38.29 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $28.13 | 2024 | Tyrvaya |
| Thea Pharma INC. | $22.32 | 2023 | Iyuzeh |
| Sight Sciences, INC. | $21.40 | 2022 | |
| Rayner Intraocular Lenses Limited | $20.08 | 2025 | Omidria |
| Medline Industries LP | $15.82 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $14.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.